The ENTRESTO market continues to demonstrate steady expansion driven by advancements in cardiovascular therapeutics and growing prevalence of heart failure globally. This market’s evolving landscape reflects ongoing innovations and strategic initiatives aligned with enhancing patient outcomes and addressing unmet medical needs.
Market Size and Overview
The global ENTRESTO market size is estimated to be valued at USD 9.09 billion in 2025 and is expected to reach USD 12.21 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.3% from 2025 to 2032. ENTRESTO Market Growth reflects rising adoption of ENTRESTO for heart failure treatments alongside increasing industry trends toward combination therapies that improve efficacy and patient adherence. Market dynamics such as regulatory approvals and reimbursement expansions also contribute to favorable business growth in this segment.
Market Segments
The ENTRESTO market segmentation can be broadly categorized into product formulation, indication, and distribution channel. Within product formulations, oral tablets dominate due to ease of administration and patient preference, with recent 2024 data showing a 5% revenue growth driven by improved bioavailability formulations. Indications are segmented into heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF), with HFrEF remaining the dominant and fastest-growing sub-segment, supported by clinical outcomes reported through 2025. Distribution channels include hospital pharmacies, retail pharmacies, and online platforms; notably, retail pharmacies have emerged as the fastest-growing channel, capitalizing on growing outpatient treatment trends.
Market Drivers
A key market driver influencing ENTRESTO market growth is the increasing global prevalence of chronic heart failure and associated comorbidities. According to 2024 epidemiological reports, over 64 million people are affected by heart failure worldwide, which heightens demand for effective therapies. Health policies focusing on improving cardiovascular disease management and accelerated regulatory approvals for expanded indications have created significant market opportunities. Furthermore, advances in personalized medicine and patient-specific dosing protocols have reinforced the market scope, reducing hospital readmission rates by approximately 15% in pilot projects reported in late 2024.
Segment Analysis
Focusing on the indication segment, heart failure with reduced ejection fraction (HFrEF) continues to contribute the majority of ENTRESTO market revenue. Clinical trials conducted between 2024 and 2025 confirm approximately 6% higher efficacy of ENTRESTO versus traditional ACE inhibitors in reducing cardiovascular mortality, thereby driving increased prescribing rates. Conversely, the HFpEF segment, though smaller, is the fastest-growing sub-segment supported by emerging clinical evidence and expanding adoption, contributing to more than 8% annual revenue growth in 2025 as reflected in healthcare utilization data.
Consumer Behaviour Insights
Recent consumer behavior insights for ENTRESTO reveal several notable trends. First, patients and healthcare providers increasingly prefer brands offering patient-centric services including personalized dosage optimization, in line with a 2024 survey where 68% of respondents prioritized tailored treatment options. Second, digital engagement platforms improved patient adherence through medication reminders and virtual consultations, evidenced by a 12% increase in prescription refill rates in 2025. Finally, sustainability considerations impacted procurement decisions at institutional buyers, with hospitals favoring ENTRESTO production processes emphasizing eco-friendly practices, as reported in sustainability reviews during 2024.
Key Players
Novartis AG remains the predominant market player in the ENTRESTO market. During 2024 and 2025, Novartis expanded production capacity by 15% and launched newer ENTRESTO dosage forms to enhance treatment customization. Other relevant market companies focused on strategic collaborations and regional market entries to strengthen their market presence. These market players adopted targeted growth strategies such as product lifecycle extensions and investment in R&D to maintain competitive advantages and drive market revenue.
Key Winning Strategies Adopted by Key Players
Among innovative market growth strategies, Novartis AG’s 2024 launch of a patient-support digital platform significantly improved patient adherence and engagement, leading to a 10% increase in repeat prescriptions within one year. Additionally, Novartis implemented a precision medicine approach by integrating AI-driven patient stratification in clinical decision-making, increasing therapeutic outcomes and optimizing resource allocation. This approach, uncommon among market companies, boosted the company’s market revenue and strengthened its industry share in key geographies, serving as a benchmark for business growth strategies in the ENTRESTO market.
Frequently Asked Questions (FAQs)
Q1. Who are the dominant players in the ENTRESTO market?
Novartis AG stands out as the leading market player, supported by product innovation and capacity expansions through 2024–2025.
Q2. What will be the size of the ENTRESTO market in the coming years?
The ENTRESTO market size is projected to rise from USD 9.09 billion in 2025 to USD 12.21 billion by 2032, with a CAGR of 4.3%.
Q3. Which indication segment has the largest growth opportunity in the ENTRESTO market?
Heart failure with preserved ejection fraction (HFpEF) is the fastest-growing indication segment due to expanding clinical evidence and treatment adoption.
Q4. How will market development trends evolve over the next five years?
Market trends will increasingly favor digital patient engagement tools, personalized medicine applications, and environmentally sustainable manufacturing processes.
Q5. What is the nature of the competitive landscape and challenges in the ENTRESTO market?
The market features high entry barriers due to strict regulatory requirements and the need for proven clinical efficacy, posing challenges for new entrants but encouraging innovation among established market players.
Q6. What go-to-market strategies are commonly adopted in the ENTRESTO market?
Strategies include capacity expansion, new formulation launches, precision medicine integration, and digital patient support platforms, aimed at enhancing market penetration and revenue growth.
Get more insights on, ENTRESTO Market
Get This Report in Japanese Language: エントレスト市場
Get This Report in Korean Language: 엔트리스토 마켓
Read More Articles Related to this Industry- How Pharmaceutical Companies are Innovating in Infertility Drug Development
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
Comments
0 comment